Filing Flows › TG Therapeutics (TGTX) › Product revenue, net revenue
TG Therapeutics (TGTX) Product revenue, net revenue by quarter
TG Therapeutics' Product revenue, net revenue was $240M in Q3 2026 (third quarter 2026), +2% from Q2 2026. Over the last 7 quarters it ranged from $120M (Q1 2025) to $240M (Q3 2026).
| Quarter | Product revenue, net revenue | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $240M | +2% | +51% |
| Q2 2026 | $236M | +17% | +70% |
| Q1 2026 | $201M | +6% | +68% |
| Q4 2025 | $189M | +19% | — |
| Q3 2025 | $159M | +15% | — |
| Q2 2025 | $139M | +16% | — |
| Q1 2025 | $120M | — | — |
Q3 2026 at a glance
TG Therapeutics, Q3 2026: revenue $260M (+61% year over year), operating margin 33.0%, net earnings $55.5M, operating cash flow $45.2M. The chart follows the revenue to costs, profit and cash.
Questions
What is TG Therapeutics' Product revenue, net revenue?
TG Therapeutics' Product revenue, net revenue was $240M in Q3 2026 (third quarter 2026), +2% from Q2 2026.
How has TG Therapeutics' Product revenue, net revenue changed?
Over the last 7 quarters it ranged from $120M (Q1 2025) to $240M (Q3 2026).